Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of PBI-4050 on the Pharmacokinetics of Midazolam, a Sensitive Cytochrome P450 3A Substrate, in Healthy Adult Subjects

Trial Profile

A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of PBI-4050 on the Pharmacokinetics of Midazolam, a Sensitive Cytochrome P450 3A Substrate, in Healthy Adult Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2018

At a glance

  • Drugs PBI 4050 (Primary) ; Midazolam
  • Indications Acute lung injury; Alstrom's Syndrome; Cystic fibrosis; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Metabolic syndrome; Pulmonary hypertension; Renal fibrosis; Scleroderma; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors ProMetic Life Sciences
  • Most Recent Events

    • 06 Sep 2018 Status changed from recruiting to active, no longer recruiting.
    • 24 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top